LUND, June 15, 2007-Active Biotech (OMX Nordic: ACTI) presented pre-clinical results for the project I-3D at the annual EULAR (The European League Against Rheumatism, www.eular.org ) conference, June 13-16*.
"The new pre-clinical data presented show that I-3D has a significant inhibitory effect on disease development in an experimental model for rheumatoid arthritis (RA)", commented Sven Andréasson, President & CEO Active Biotech.
An additive inhibitory effect on disease development is achieved when I-3D is combined with methotrexate, an anti-proliferative drug widely used for the treatment of various inflammatory disorders and cancer.
The results strengthen further clinical development of I-3D as monotherapy or in combination with methotrexate.
Lund, June 15, 2007
Active Biotech AB (publ)
Sven Andréasson President and CEO
About I-3D The I-3D compound is a novel small molecule inhibitor of human dihydroorotate dehydrogenase (DHODH). Inflammatory diseases such as RA involve rapidly proliferating T cells with an exceptional requirement for de novo pyrimidine biosynthesis. DHODH inhibition results in inhibition of de novo pyrimidine synthesis and thereby inhibition of T-cell proliferation.
In May 2006, Active Biotech and Chelsea Therapeutics International Ltd (NASDAQ:CHTP) signed an agreement for the co-development and commercialization of I-3D. Under the agreement, Active Biotech and Chelsea will jointly conduct and fund the clinical development of the I-3D portfolio.
A candidate drug is planned to be selected this year for further clinical trials in 2008.
*For further information and to view the complete poster "ABR-224050: a novel dihydroorotate dehydrogenase inhibitor suppressing disease development in collagen induced arthritis", please visit www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics International Ltd.
Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 20 50